David Lebowitz
Stock Analyst at Citigroup
(3.19)
# 1,031
Out of 4,869 analysts
113
Total ratings
48.75%
Success rate
0.83%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Upgrades: Neutral | $83 → $129 | $128.20 | +0.62% | 6 | Jun 4, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $40.37 | +38.72% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $9.20 | +8.70% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $32.43 | +146.69% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.28 | +17.19% | 6 | Mar 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $41.73 | +17.42% | 4 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $37.41 | +71.08% | 12 | Feb 20, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $50.20 | -10.36% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $68.46 | +28.54% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $26.01 | +46.10% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $50.39 | +34.95% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $20.50 | +241.55% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.23 | +107.47% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $176.47 | +17.30% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $20.46 | +80.84% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $285.73 | +33.69% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $55.00 | +74.55% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $2.56 | +368.75% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $309.70 | -47.05% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.82 | +182.20% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $9.48 | +121.52% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.42 | +9,062.90% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.70 | +1,895.44% | 2 | Oct 12, 2021 |
Blueprint Medicines
Jun 4, 2025
Upgrades: Neutral
Price Target: $83 → $129
Current: $128.20
Upside: +0.62%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $40.37
Upside: +38.72%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.20
Upside: +8.70%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $32.43
Upside: +146.69%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.28
Upside: +17.19%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $41.73
Upside: +17.42%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $37.41
Upside: +71.08%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $50.20
Upside: -10.36%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $68.46
Upside: +28.54%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $26.01
Upside: +46.10%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $50.39
Upside: +34.95%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $20.50
Upside: +241.55%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.23
Upside: +107.47%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $176.47
Upside: +17.30%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $20.46
Upside: +80.84%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $285.73
Upside: +33.69%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $55.00
Upside: +74.55%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $2.56
Upside: +368.75%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $309.70
Upside: -47.05%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.82
Upside: +182.20%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $9.48
Upside: +121.52%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.42
Upside: +9,062.90%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.70
Upside: +1,895.44%